Executive Summary

ER-100 represents an unusually direct test of partial epigenetic reprogramming in humans. Rather than replacing retinal neurons or primarily modifying an upstream disease risk factor, the therapeutic concept is to alter the cellular state of surviving retinal ganglion cells using controlled expression of OCT4, SOX2 and KLF4.

The preclinical package is notable because the reported nonhuman primate effect is not limited to molecular biomarkers. ER-100 produced retinal target engagement, changes in DNA methylation, structural preservation and improvement in pattern electroretinography, an electrophysiologic measure closely linked to retinal ganglion cell function.

The existing treatment landscapes for the two diseases create different regulatory opportunities. NAION currently has no FDA-approved disease-directed treatment, while open-angle glaucoma has numerous approved therapies that reduce intraocular pressure. None of those glaucoma products is approved specifically to restore retinal ganglion cell function after neuronal damage.

The regulatory challenge now shifts from demonstrating biological activity to defining clinical benefit. FDA review will likely depend heavily on whether improvements in retinal electrophysiology align with visual fields, contrast sensitivity, visual acuity and durable structural preservation, while the program simultaneously addresses AAV immunogenicity, ocular inflammation, transgene control, biodistribution, shedding, potency and long-term safety.

An important biological hypothesis underlying the program is that optic neuropathies may leave a therapeutically accessible population of retinal ganglion cells that are alive but dysfunctional. If ER-100 can restore function in those cells, the ceiling for recovery could depend less on the amount of visual dysfunction at presentation than on how much viable neuronal substrate remains.

ER-100 Crosses Into Human Testing

Life Biosciences announced in January 2026 that the U.S. Food and Drug Administration had cleared the Investigational New Drug application for ER-100, permitting clinical evaluation in open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. The company subsequently announced that the first participant was dosed on June 9, 2026. ER-100 is an investigational adeno-associated virus serotype 2, or AAV2, gene therapy designed to produce controlled expression of the transcription factors OCT4, SOX2 and KLF4, collectively referred to as OSK, in retinal cells. 123

The Phase 1 study, NCT07290244, is designed primarily to evaluate the safety and tolerability of a single intravitreal administration. Systemic doxycycline is administered for 56 days to activate OSK expression, and participants undergo extended follow-up after treatment. 3

The publicly confirmed ER-100 development pathway can also be explored in Regulatory Designer, which maps disclosed clinical and regulatory milestones across the program.

This clinical entry is regulatory validation of permission to test ER-100, not evidence that FDA has concluded that epigenetic reprogramming is safe or effective. The distinction is particularly important for a first-in-class mechanism. IND clearance establishes that the available manufacturing, nonclinical and clinical information was sufficient to allow the proposed first-in-human study to proceed, while the evidentiary standard for marketing authorization remains substantially higher. 14

A Very Different Treatment Landscape in NAION and Glaucoma

ER-100 is being developed across two optic neuropathies with markedly different existing treatment landscapes. There is currently no FDA-approved treatment specifically indicated to reverse, repair or treat the underlying neuronal injury in non-arteritic anterior ischemic optic neuropathy, or NAION. Management therefore centers on clinical assessment and management of relevant systemic and ocular risk factors rather than an approved disease-modifying therapy capable of restoring the affected retinal ganglion cells. 25

Where ER-100 Could Fit in Optic Neuropathy Treatment

Click to enlarge

Open-angle glaucoma, in contrast, has a mature therapeutic armamentarium. FDA-approved products include prostaglandin analogs, beta-adrenergic antagonists, alpha-adrenergic agonists, Rho kinase inhibitors, fixed combinations and sustained intraocular drug-delivery products. These therapies differ in mechanism and route of delivery, but their approved therapeutic objective is principally reduction of elevated intraocular pressure rather than restoration of retinal ganglion cells that have already become dysfunctional. 678910111213

The table below is representative rather than exhaustive and focuses on FDA-approved pharmacologic products relevant to open-angle glaucoma. Laser procedures, incisional glaucoma surgery and glaucoma devices are not intended to be comprehensively represented. 678910111213

Why the Existing Landscape Matters for FDA Review

The absence of an approved NAION therapy potentially gives ER-100 a comparatively clear unmet-need setting. If treatment after NAION could reproducibly preserve or recover clinically meaningful visual function, the development program would be addressing an outcome not currently achieved by an FDA-approved disease-specific pharmacologic therapy. The regulatory challenge would still be to establish that observed recovery exceeds natural history and measurement variability and that the magnitude of benefit is clinically meaningful. 253

The glaucoma case is different. FDA already has extensive experience reviewing therapies that lower intraocular pressure, and numerous products are approved for that purpose. ER-100 therefore has the potential to occupy a fundamentally different therapeutic position if it can demonstrate preservation or restoration of retinal ganglion cell function beyond what would be expected from pressure control alone. 69133

That distinction could eventually affect trial design and labeling strategy. An ER-100 program centered on neuronal restoration would need endpoints capable of demonstrating functional benefit rather than simply showing another reduction in intraocular pressure. Visual-field performance, contrast sensitivity, visual acuity, retinal electrophysiology and structural measures could therefore become important components of an integrated evidence package, although the endpoints acceptable for a future registrational program have not been established. 314

The Primate Signal Behind the IND

The translational argument for ER-100 is strengthened by experiments in nonhuman primates using a laser photothrombosis model intended to reproduce important features of non-arteritic anterior ischemic optic neuropathy, or NAION. In a 2023 characterization of this model in African green monkeys, pattern electroretinography, or pERG, showed a fall in absolute N95 amplitude from approximately 6.9 ± 1.2 µV at baseline to approximately 2.6 µV at Day 42, demonstrating a large and persistent functional deficit after injury. 15

Earlier disclosed OSK experiments provide additional context. In a post-injury treatment experiment, the P50-N95 pERG amplitude five weeks after laser injury was 4.60 ± 0.24 µV with OSK compared with 2.89 ± 0.79 µV in vehicle-treated eyes, corresponding to approximately 59 percent higher amplitude in the treated group. A pretreatment experiment reported amplitudes of 5.36 ± 0.91 µV with OSK and 3.95 ± 1.01 µV with vehicle, although that comparison was not statistically significant. 16

At the 2026 Association for Research in Vision and Ophthalmology meeting, investigators reported that ER-100 produced perifoveal OCT4, SOX2 and KLF4 expression in approximately 10 to 25 percent of cells in the ganglion cell layer, reversed NAION-associated DNA methylation changes in a retinal ganglion cell-enriched population, improved pERG amplitudes by approximately 2 to 3 µV and mitigated retinal architectural damage. The abstract also reported transient procedure-related and AAV2-associated ocular inflammation, stable intraocular pressure and no adverse effect on outer retinal function measured by full-field electroretinography. 17

What a 2 to 3 µV Effect Could Mean

The absolute magnitude of a pERG change cannot be translated directly into Snellen visual acuity or a percentage improvement in human sight. pERG records a small electrophysiologic response generated in substantial part by retinal ganglion cell activity, and absolute amplitudes depend on stimulus parameters, electrode configuration, signal processing and laboratory methodology. N95 reduction is characteristic of retinal ganglion cell and optic nerve dysfunction, making the measure useful as a functional readout but not interchangeable with a patient-reported visual outcome. 18

The historical primate data nevertheless provide a useful scale for interpreting the 2026 result. Using the approximately 6.9 µV historical baseline and approximately 2.6 to 3.0 µV post-injury range as a heuristic, an additional 2 to 3 µV could place a treated eye roughly in the 4.6 to 6.0 µV range, or approximately two-thirds to nearly nine-tenths of the historical baseline amplitude. This is a cross-study extrapolation rather than a reported ER-100 efficacy analysis, because the full contemporaneous baseline and control distributions from the 2026 dataset have not been provided in the abstract. 151716

The older post-injury experiment provides another way to express the effect. Comparing the historical 6.9 µV model baseline with 2.89 µV in vehicle and 4.60 µV after OSK suggests that approximately 43 percent of the electrophysiologic deficit relative to baseline was recovered. That calculation combines values from related but separate experiments and should therefore be treated as an illustrative estimate rather than a formal treatment-effect statistic. 1516

For human translation, the more important question is whether an increase in pERG is accompanied by improvement in what patients can actually see. The Phase 1 program includes functional and structural visual assessments that can begin to examine whether retinal electrophysiologic changes correspond to broader evidence of visual benefit. 31

A Phase 1 Designed Around Uncertainty

The clinical study proceeds through dose evaluation in open-angle glaucoma before expansion into NAION. The registered study uses sequential dose escalation with safety review and then evaluates NAION using experience accumulated during the glaucoma portion of the program. 3

This structure is well aligned with the principal uncertainty in a first-in-human reprogramming program: the relevant early clinical question is not simply whether OSK has biological activity, but how much expression can be induced in human retinal tissue without unacceptable ocular, immune or systemic toxicity. The doxycycline-controlled expression period adds a pharmacologic control layer to a gene therapy whose vector may persist beyond the period of intended transgene activation. 32

The study incorporates detailed ocular safety assessments, immune monitoring, shedding and biodistribution-related assessments and extended clinical follow-up. These measures reflect the types of safety, immunogenicity, persistence and delayed-risk questions that are important in gene therapy development. 31419

What FDA Is Likely to Scrutinize

ER-100 falls squarely within FDA's gene therapy framework. The Center for Biologics Evaluation and Research has specific guidance addressing gene therapy for retinal disorders, including product development, nonclinical testing and clinical trial design. If the program ultimately supports marketing authorization, a CBER-regulated gene therapy would ordinarily proceed through a Biologics License Application, which requires an integrated demonstration of safety, purity and potency together with adequate clinical evidence supporting the intended use. 144

Chemistry, manufacturing and controls may be particularly important for a therapy whose biological effect depends on controlled expression of three transcription factors. FDA's gene therapy CMC guidance requires sufficient information to establish product safety, identity, quality, purity and strength, including potency. For ER-100, a central development challenge will therefore be establishing assays and manufacturing controls that connect vector attributes with reproducible delivery and biologically appropriate OSK activity without uncontrolled expression. The specific commercial potency strategy has not been publicly disclosed. 20

Long-term safety will remain important even though OSK activation is intended to be temporally controlled. FDA notes that gene therapies may produce permanent or long-acting changes and recommends extended follow-up when delayed adverse events are biologically plausible. ER-100's registered study incorporates extended follow-up, creating an opportunity to examine ocular inflammation, immune responses, retinal structure and other delayed findings beyond the active doxycycline induction period. 193

The efficacy discussion may ultimately be more complex than the safety discussion. pERG is an attractive translational marker because it directly interrogates retinal ganglion cell function and generated a measurable signal in the primate program. It is not, however, equivalent to demonstrating a clinically meaningful improvement in vision. A future development program would be substantially strengthened if changes in pERG consistently track improvements in prespecified visual-field, contrast-sensitivity or acuity measures. FDA's Office of Therapeutic Products provides formal meeting mechanisms through which novel endpoint strategies can be discussed during development. 321

A particularly important review question may concern the boundary between rejuvenation and reprogramming. The therapeutic hypothesis requires enough epigenetic change to improve neuronal function while preserving retinal ganglion cell identity and avoiding inappropriate proliferation or other pathological cell-state changes. Mouse experiments with OSK were designed around partial rather than complete reprogramming and reported restoration of visual function, but the human therapeutic window can only be established clinically. 22233

The Therapeutic Substrate May Be Injured, Living RGCs

The concept of recovering visual function does not require resurrection of retinal ganglion cells that have already died. A more plausible biological interpretation is that optic nerve injury creates a spectrum ranging from normally functioning neurons through stressed and electrophysiologically impaired neurons to irreversible degeneration. Pattern electroretinography can detect retinal ganglion cell dysfunction before equivalent structural loss is detectable by optical coherence tomography in glaucoma-suspect populations. 24

Human glaucoma studies also provide evidence that some retinal ganglion cell dysfunction can be reversible. Pattern electroretinogram amplitudes have improved after intraocular-pressure-lowering treatment, supporting the presence of viable retinal ganglion cells whose function is suppressed rather than permanently lost. This does not establish that ER-100 will reproduce the same effect, but it supports the broader biological premise that diminished electrophysiologic activity does not necessarily mean that every affected neuron is dead. 25

ER-100 itself further implies a requirement for viable cellular substrate because a living transduced cell is needed to express OCT4, SOX2 and KLF4. The preclinical observations are therefore most consistent with some combination of functional restoration in surviving retinal ganglion cells, protection of threatened cells and preservation or repair of their axons. The existing evidence does not demonstrate replacement of retinal ganglion cells that have already been eliminated. 222317

This distinction could eventually become important for patient selection. A patient may have substantial functional impairment while retaining enough anatomically connected but dysfunctional retinal ganglion cells to provide a substrate for recovery, whereas very advanced neuronal loss could impose a biological ceiling regardless of how effectively surviving cells are reprogrammed. This remains a testable hypothesis rather than an established clinical predictor of ER-100 response. 24253

Glaucoma Changes the Therapeutic Question

NAION and glaucoma create different tests of the ER-100 hypothesis. NAION is an acute ischemic injury followed by secondary degeneration, whereas open-angle glaucoma exposes retinal ganglion cells to a chronic disease process in which elevated intraocular pressure is an important modifiable risk factor. ER-100 is not being developed as an intraocular-pressure-lowering therapy. Its proposed role is downstream, at the level of damaged retinal ganglion cells. 23

The distinction matters because lowering intraocular pressure and restoring neuronal function are not mutually exclusive therapeutic objectives. In mouse glaucoma experiments, OSK was administered after microbead-induced ocular hypertension had already produced measurable visual dysfunction, and subsequent treatment restored visual function. The data support a neurorestorative interpretation rather than an explanation based solely on preventing the initial pressure insult. 23

For human glaucoma, the most plausible clinical use would therefore be additive to appropriate pressure control rather than a substitute for it. Pressure-lowering therapy can reduce the ongoing upstream insult, while an effective retinal ganglion cell therapy could theoretically improve resilience, preserve threatened neurons or restore function in cells that remain viable. Whether ER-100 can provide such benefit when glaucomatous stress persists is one of the questions that human longitudinal data will need to resolve. 23253

The existing glaucoma market makes this distinction particularly important from a regulatory perspective. Products such as Xalatan, Rhopressa, Durysta and iDose TR already provide pharmacologic routes to reduce intraocular pressure. ER-100 would be substantially differentiated only if its effect is shown at the level of the injured neuronal system itself, particularly if improvement can be demonstrated after measurable visual dysfunction has occurred. 6912133

This also creates an important regulatory distinction between structural preservation and functional restoration. A therapy that slows additional retinal nerve fiber layer loss could support a neuroprotective therapeutic proposition, while reproducible improvement in visual-field sensitivity, contrast sensitivity or other visual measures after established damage could support a substantially different proposition centered on restoration. The current Phase 1 program can begin to distinguish these possibilities, but later controlled studies would be required to establish the magnitude and clinical significance of any restorative effect. 314

From Phase 1 to a Potential BLA

If ER-100 progresses, FDA review would ultimately be expected to occur within the biological-product framework administered by CBER. A Biologics License Application is the formal marketing application for a CBER-regulated biological product and requires comprehensive clinical, nonclinical, manufacturing and facility information sufficient to support licensure. No ER-100 BLA strategy or pivotal-study design has been publicly specified. 4

The first major regulatory inflection point may therefore be dose and endpoint selection rather than an immediate decision about an expedited approval pathway. Acceptable ocular safety and reproducible improvement across retinal electrophysiology and conventional visual-function measures could provide the foundation for FDA discussions addressing population selection, control strategy, endpoint hierarchy, duration of follow-up and the evidentiary requirements for subsequent trials. FDA's Office of Therapeutic Products provides formal meeting pathways for these development questions. 213

Regenerative Medicine Advanced Therapy designation could also become relevant, although no such designation for ER-100 has been publicly identified. FDA states that certain human gene therapies may qualify as regenerative medicine therapies and that RMAT designation requires treatment of a serious condition together with preliminary clinical evidence indicating the potential to address an unmet medical need. Consequently, persuasive human evidence rather than the existing primate efficacy package would be central to a future RMAT request. 26

Accelerated approval is conceptually more difficult to assess at this stage. A development strategy centered on a surrogate endpoint would require confidence that the measure is sufficiently predictive of clinical benefit in the proposed context. pERG could become a valuable pharmacodynamic or supportive efficacy marker, but there is currently insufficient public evidence to assume that a pERG amplitude improvement alone could support approval. Early FDA discussion would be particularly important before elevating it to a pivotal surrogate role. 2143

The indication itself may influence development strategy. NAION offers a setting with no currently approved disease-directed therapy, potentially creating a particularly clear unmet-need argument if ER-100 demonstrates meaningful recovery or preservation of vision. Glaucoma presents a different problem because effective pressure-lowering therapies are already available. In that indication, the regulatory and clinical value proposition for ER-100 would likely depend on demonstrating benefit that is distinct from, and additive to, control of intraocular pressure. 256913

Conclusion

ER-100 has reached a point at which the central question is no longer whether partial epigenetic reprogramming can produce interesting biology in an animal model. The program is now testing whether controlled OSK expression can be delivered safely to humans and whether molecular and electrophysiologic changes translate into meaningful restoration or preservation of vision.

The treatment context makes the program particularly unusual. In NAION, ER-100 could potentially address a disease for which no FDA-approved disease-directed therapy currently exists. In glaucoma, it could test a therapeutic concept fundamentally different from the established pressure-lowering paradigm by targeting the damaged retinal ganglion cell itself.

The primate pERG results provide a potentially important signal. Viewed against historical values from the same model, an improvement of a few microvolts could represent recovery of a substantial fraction of injury-associated retinal ganglion cell function. That interpretation remains provisional until complete contemporaneous datasets and human results are available.

The most consequential possibility is that some vision traditionally considered irreversibly lost may instead reflect a mixture of neuronal death and recoverable neuronal dysfunction. ER-100 cannot be expected to restore cells that no longer exist, but it may test whether surviving, damaged retinal ganglion cells retain more functional capacity than their clinical presentation suggests.

For FDA, success will require those biological concepts to become measurable regulatory evidence: a controlled and reproducible gene therapy product, acceptable short- and long-term safety, a defined therapeutic window and convincing improvement in clinically meaningful visual function. The first Phase 1 data will therefore matter far beyond ER-100 itself, because they may begin defining how partial epigenetic reprogramming can be evaluated as a therapeutic modality.